Alzheimer’s Disease  – Transgenic Tau Mouse Models

Test potential therapeutics for Alzheimer’s disease and other Tauopathies in Transgenic Tau mouse models with Tau deposition and the downstream pathological events

Home » Neurology CRO Services » Alzheimer’s Models Disease Mouse Models » Transgenic Tau Mouse Models

Transgenic Tau Mouse Models Key Characteristics

The histopathological hallmarks of Alzheimer’s disease (AD) are extracellular plaques composed of amyloid beta (Aβ) and intracellular inclusions of the protein Tau (neurofibrillary tangles). Tau is encoded by the microtubule-associated protein tau (MAPT) gene. Tau pathology in AD and other Tauopathies such as frontotemporal dementia (FTD) is strongly associated with neurodegeneration and clinical symptoms. 

Transgenic mouse models overexpressing human Tau with disease associated MAPT mutations display abundant tau pathology, neuroinflammation, neurodegeneration, and behavioural impairments; making them ideal models to test therapeutic interventions for AD and other tauopathies. Transgenic Tau mouse models recapitulating the Tau pathology are suitable for testing compounds for AD, but also a range of other Tauopathies (FTD, frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, Pick’s disease). InnoSer additionally offers Tau seeding models using recombinant and/or patient derived seeds or alternatively APP transgenic mice which recapitulate the amyloid beta pathology of Alzheimer’s disease. However, as each model is unique, modelling distinct pathophysiological aspects of Alzheimer’s disease, we recommend you discuss the most appropriate model with our neurology study directors. 

European based preclinical CRO offering Infantile Epileptic Encaphalopathy Stxbp1 mouse models for drug development

InnoSer offers expert guidance and a collaborative approach to selecting the best model for your research, as the models we offer present varying degrees of neurofibrillary tangles, neuroinflammation, neurodegeneration, and behavioral deficits.  

InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types, including small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors, e.g., AAVs), and immunotherapies (antibody/vaccine immunotherapies). 

Your Alzheimer’s Disease Research Starts Here.

Explore our expertly curated comparison of available mouse models to make faster, data-driven decisions. View example study timeline, recommended readouts, and example data featuring validation datasets across the different mouse models.

ALS sample data leaflet download preclinical mouse models of ALS

Transgenic Tau Mouse Models Sample Data

Transgenic Tau Mouse Models Readouts

Key Behavioral Readouts in the Transgenic Tau Mouse Model


Test the efficacy of your treatments in the following battery of behavioral tests:

View Complete Catalogue

Biological Readouts

Test the efficacy of your treatments with the following biological readouts: 
  
  • MSD: Plasma, CSF, and brain (pTau, cytokines, NF-L) 
  • (Digital) histopathology 
  • Immunohistochemistry (e.g.,  pTau, neuroinflammation, neurodegeneration) 
  • Immunofluorescence and FISH 

    The People Behind Your Research

    Thomas Vogels, PhD Neurology study director InnoSer

    Thomas Vogels, PhD, In Vivo Neurology Study Director

    Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.

    Discover InnoSer’s Latest Research

    AAALAC Accreditation

    InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

    AAALAC logo

    Animal Welfare

    The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

    No Obligation – Get Started

    info@innoserlaboratories.com